Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.77 USD
Change Today +0.52 / 2.24%
Volume 1.9K
GLAXF On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GLAXF) Snapshot

Open
$23.52
Previous Close
$23.25
Day High
$23.77
Day Low
$23.52
52 Week High
04/29/14 - $28.45
52 Week Low
12/16/14 - $20.50
Market Cap
115.6B
Average Volume 10 Days
1.7K
EPS TTM
--
Shares Outstanding
4.9B
EX-Date
02/19/15
P/E TM
--
Dividend
$97.07
Dividend Yield
6.05%
Current Stock Chart for GLAXOSMITHKLINE PLC (GLAXF)

glaxosmithkline plc (GLAXF) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc (GLAXF) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc (GLAXF) Key Developments

GlaxoSmithKline Announces More Layoffs

GlaxoSmithKline announced another round of layoffs affecting 180 workers in North Carolina. The affected positions are in sales, marketing, operations and other managerial, technical and support roles.

Cold Spring Harbor Laboratory Announces Collaboration with GSK to Develop Treatment for Obesity and Type 2 Diabetes

Cold Spring Harbor Laboratory (CSHL) announced a collaboration with GSK to develop a treatment for obesity and type 2 diabetes. Scientists at CSHL and GSK will pursue drug development based on a novel approach to regulate the enzymatic activity of the phosphatase PTP1B. The goal of the multi-year CSHL-GSK collaboration is to identify potent, selective, orally bioavailable small molecules that inhibit PTP1B activity in vivo following stimulation by insulin and leptin, which would be expected to overcome insulin and leptin resistance that is encountered in diabetes and obesity. The work at CSHL will be led by Professor Nicholas Tonks, who is an expert on the protein tyrosine phosphatase (PTP) family of enzymes and their roles in human diseases. GSK and CSHL will provide project co-leadership, allowing synergy between their different sets of expertise to facilitate the development of novel therapeutics.

GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO ELLIPTA in Asthma

GlaxoSmithKline plc and Theravance Inc. announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States (US) Food and Drug Administration (FDA) regarding the supplemental New Drug Application (sNDA) for BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLAXF:US $23.77 USD +0.52

GLAXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $163.50 USD +0.91
AbbVie Inc $57.65 USD +0.38
Actavis plc $303.56 USD +2.24
Amgen Inc $162.59 USD +2.04
Novo Nordisk A/S kr371.70 DKK +2.00
View Industry Companies
 

Industry Analysis

GLAXF

Industry Average

Valuation GLAXF Industry Range
Price/Earnings 26.5x
Price/Sales 3.1x
Price/Book 16.9x
Price/Cash Flow 26.5x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.